Russia inks pact to test, supply Sputnik V vaccine to India  09/16/2020 18:00:29 

The Russia Direct Investment Fund (RDIF), which is piloting Russias Sputnik V candidate vaccine, currently in Phase 3 trials, has partnered with the Hyderabad-based Dr. Reddys Laboratories to test, and subject to regulatory approvals in India, supply 100 million doses of the vaccine.

G.V. Prasad, co-chairman and managing director, Dr. Reddys Laboratories, said in a joint statement with RDIF: We are pleased to partner with RDIF to bring the vaccine to India. The Phase 1 and 2 results have shown promise, and we will be conducting Phase 3 trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India.

Russian COVID-19 vaccine | Sputnik V is safe and effective, says RDIF CEO

The RDIF said in the statement, The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

The agreement does not include manufacturing the vaccine in India. An RDIF spokesperson said the organisation was still looking for manufacturers.

The Dr. Reddys-RDIF agreement constitutes the second major international deal for supplying a potential vaccine after the agreement between British company AstraZeneca and the Pune-based Serum Institute of India (SII). The latter will manufacture 100 million doses of the vaccine, of which reportedly half will be for India.

Russian COVID-19 vaccine | Scientists alert The Lancet to potential data inconsistencies in Russian vaccine trial paper

On August 11, the Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform. Detailed information on the vaccine, the technological platform of human adenoviral vectors, and other details are available at

On September 4, a research paper on the results of Phase I and Phase II clinical trials of the vaccine was published in The Lancet, a peer-reviewed international medical journal, demonstrating no serious adverse effects and a stable immune response in 100% of the participants. Post-registration clinical trials involving 40,000 volunteers are currently on. More than 55,000 volunteers had applied to take part in the trials. The first results are expected to be published in October-November.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

« Go back